誠邁科技(300598.SZ):公司對統信軟件沒有並表,統信軟件在推動自身上市計劃
格隆匯6月1日丨誠邁科技(300598.SZ)於2023年05月31日上午9:30-11:00參與深圳證券交易所舉辦“走進上市公司—誠邁科技”活動,交流環節中,就“統信軟件業務發展情況?”,公司回覆稱,公司已發佈一季報,在投資收益部分説明了統信軟件2023年一季度收入同比改善,虧損減小,相應公司投資虧損有所改善。希望未來隨着重點行業企業對自主操作系統採購需求的增加,統信軟件能更加發揮產品優勢,逐步改善收入利潤。公司對統信軟件沒有並表,統信軟件在推動自身上市計劃,有具體進度時投資者通常也能查詢到公開信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.